You do realized VDRM is a penny stock in the earliest phase of it's development, right? How would you suggest management rise funds to expedite an aggressive growth plan as Viadrema's.
It takes a lot of money to bring new products to market and if management needs to rise money by selling shares; I'm okay with that, as long as it is done conservatively, responsibly and only as needed until income offsets the cost.
So far management has proven to be both conservative and responsible therefore retaining my trust, investment and support.